image
Healthcare - Medical - Devices - NYSE - US
$ 138.44
-0.13 %
$ 7.63 B
Market Cap
-47.41
P/E
1. INTRINSIC VALUE

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally.[ Read More ]

The intrinsic value of one GKOS stock under the base case scenario is HIDDEN Compared to the current market price of 138 USD, Glaukos Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart GKOS

image
FINANCIALS
315 M REVENUE
11.26%
-129 M OPERATING INCOME
-25.79%
-135 M NET INCOME
-35.75%
-57.8 M OPERATING CASH FLOW
-74.59%
14.1 M INVESTING CASH FLOW
-68.52%
15 M FINANCING CASH FLOW
140.63%
96.7 M REVENUE
1.02%
-24.7 M OPERATING INCOME
10.24%
-21.4 M NET INCOME
57.64%
-9.59 M OPERATING CASH FLOW
47.81%
30.6 M INVESTING CASH FLOW
-12.34%
9.67 M FINANCING CASH FLOW
12.52%
Balance Sheet Decomposition Glaukos Corporation
image
Current Assets 395 M
Cash & Short-Term Investments 295 M
Receivables 39.8 M
Other Current Assets 60.2 M
Non-Current Assets 545 M
Long-Term Investments 0
PP&E 175 M
Other Non-Current Assets 370 M
Current Liabilities 74 M
Accounts Payable 13.4 M
Short-Term Debt 2.23 M
Other Current Liabilities 58.3 M
Non-Current Liabilities 405 M
Long-Term Debt 384 M
Other Non-Current Liabilities 20.9 M
EFFICIENCY
Earnings Waterfall Glaukos Corporation
image
Revenue 315 M
Cost Of Revenue 75.6 M
Gross Profit 239 M
Operating Expenses 368 M
Operating Income -129 M
Other Expenses 5.96 M
Net Income -135 M
RATIOS
75.99% GROSS MARGIN
75.99%
-40.89% OPERATING MARGIN
-40.89%
-42.79% NET MARGIN
-42.79%
-29.16% ROE
-29.16%
-14.32% ROA
-14.32%
-17.41% ROIC
-17.41%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Glaukos Corporation
image
Net Income -135 M
Depreciation & Amortization 38 M
Capital Expenditures -20.2 M
Stock-Based Compensation 43.5 M
Change in Working Capital -10.1 M
Others -4.48 M
Free Cash Flow -78 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Glaukos Corporation
image
Wall Street analysts predict an average 1-year price target for GKOS of $134 , with forecasts ranging from a low of $110 to a high of $155 .
GKOS Lowest Price Target Wall Street Target
110 USD -20.54%
GKOS Average Price Target Wall Street Target
134 USD -3.15%
GKOS Highest Price Target Wall Street Target
155 USD 11.96%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Glaukos Corporation
image
Sold
0-3 MONTHS
1.35 M USD 2
3-6 MONTHS
4.9 M USD 4
6-9 MONTHS
23.7 M USD 5
9-12 MONTHS
31.9 M USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 weeks ago
Oct 30, 2024
Sell 316 K USD
Gilliam Joseph E
PRESIDENT & COO
- 2275
138.97 USD
2 months ago
Sep 09, 2024
Sell 262 K USD
Kliman Gilbert H
Director
- 2000
131 USD
2 months ago
Sep 09, 2024
Sell 130 K USD
Kliman Gilbert H
Director
- 1000
130 USD
2 months ago
Aug 21, 2024
Sell 571 K USD
Gilliam Joseph E
PRESIDENT & COO
- 4420
129.27 USD
2 months ago
Aug 21, 2024
Sell 75.4 K USD
Gilliam Joseph E
PRESIDENT & COO
- 580
130.03 USD
3 months ago
Aug 15, 2024
Sell 74.4 K USD
Stapley Marc
Director
- 600
123.98 USD
3 months ago
Aug 15, 2024
Sell 139 K USD
Stapley Marc
Director
- 1110
125.28 USD
3 months ago
Aug 15, 2024
Sell 500 K USD
Stapley Marc
Director
- 3959
126.27 USD
3 months ago
Aug 15, 2024
Sell 73.7 K USD
Stapley Marc
Director
- 581
126.91 USD
3 months ago
Aug 08, 2024
Sell 3 M USD
WEISNER AIMEE S
Director
- 25000
120 USD
4 months ago
Jul 05, 2024
Sell 273 K USD
Gilliam Joseph E
PRESIDENT & COO
- 2250
121.39 USD
5 months ago
Jun 03, 2024
Sell 155 K USD
Gilliam Joseph E
PRESIDENT & COO
- 1374
112.84 USD
5 months ago
Jun 03, 2024
Sell 107 K USD
Gilliam Joseph E
PRESIDENT & COO
- 936
114.22 USD
5 months ago
Jun 03, 2024
Sell 21.8 K USD
Gilliam Joseph E
PRESIDENT & COO
- 190
114.73 USD
5 months ago
May 30, 2024
Sell 560 K USD
Kliman Gilbert H
Director
- 5000
112 USD
6 months ago
May 15, 2024
Sell 229 K USD
Stapley Marc
Director
- 2050
111.82 USD
6 months ago
May 15, 2024
Sell 248 K USD
Stapley Marc
Director
- 2200
112.91 USD
6 months ago
May 15, 2024
Sell 227 K USD
Stapley Marc
Director
- 2000
113.68 USD
6 months ago
May 10, 2024
Sell 265 K USD
Gilliam Joseph E
PRESIDENT & COO
- 2395
110.56 USD
6 months ago
May 10, 2024
Sell 34.9 K USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 316
110.43 USD
6 months ago
May 10, 2024
Sell 4.12 K USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 37
111.22 USD
6 months ago
May 06, 2024
Sell 11.6 K USD
Gilliam Joseph E
PRESIDENT & COO
- 105
110.36 USD
6 months ago
May 06, 2024
Sell 9.92 K USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 90
110.26 USD
6 months ago
May 02, 2024
Sell 35.3 K USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 335
105.25 USD
6 months ago
May 02, 2024
Sell 6.93 K USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 65
106.58 USD
6 months ago
May 02, 2024
Sell 4.53 K USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 42
107.77 USD
6 months ago
May 02, 2024
Sell 67.4 K USD
Gilliam Joseph E
PRESIDENT & COO
- 645
104.43 USD
6 months ago
May 02, 2024
Sell 70.8 K USD
Gilliam Joseph E
PRESIDENT & COO
- 672
105.31 USD
6 months ago
May 02, 2024
Sell 61.4 K USD
Gilliam Joseph E
PRESIDENT & COO
- 577
106.39 USD
6 months ago
May 02, 2024
Sell 17.8 K USD
Gilliam Joseph E
PRESIDENT & COO
- 165
107.58 USD
7 months ago
Apr 08, 2024
Sell 1.04 M USD
Gilliam Joseph E
PRESIDENT & COO
- 10456
99.64 USD
7 months ago
Apr 08, 2024
Sell 4.13 M USD
Gilliam Joseph E
PRESIDENT & COO
- 41068
100.52 USD
7 months ago
Apr 08, 2024
Sell 830 K USD
Gilliam Joseph E
PRESIDENT & COO
- 8191
101.28 USD
7 months ago
Apr 08, 2024
Sell 8.78 K USD
Gilliam Joseph E
PRESIDENT & COO
- 86
102.13 USD
7 months ago
Apr 05, 2024
Sell 1.72 K USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 18
95.55 USD
7 months ago
Apr 05, 2024
Sell 21 K USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 217
96.62 USD
7 months ago
Apr 05, 2024
Sell 2.63 K USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 27
97.4 USD
7 months ago
Apr 08, 2024
Sell 14.7 K USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 145
101.24 USD
7 months ago
Apr 08, 2024
Sell 123 K USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 1227
100.46 USD
7 months ago
Apr 05, 2024
Sell 238 K USD
Gilliam Joseph E
PRESIDENT & COO
- 2457
96.81 USD
7 months ago
Apr 03, 2024
Sell 19.3 K USD
Gilliam Joseph E
PRESIDENT & COO
- 200
96.61 USD
7 months ago
Apr 04, 2024
Sell 19.3 K USD
Gilliam Joseph E
PRESIDENT & COO
- 200
96.57 USD
7 months ago
Apr 03, 2024
Sell 29.9 K USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 316
94.62 USD
7 months ago
Apr 04, 2024
Sell 26.3 K USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 276
95.42 USD
7 months ago
Apr 04, 2024
Sell 15 K USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 158
95.16 USD
7 months ago
Apr 02, 2024
Sell 3.91 K USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 44
88.76 USD
7 months ago
Apr 02, 2024
Sell 15.3 K USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 170
89.71 USD
7 months ago
Apr 02, 2024
Sell 16.2 K USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 178
90.76 USD
7 months ago
Apr 02, 2024
Sell 7.43 K USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 81
91.74 USD
7 months ago
Apr 02, 2024
Sell 92.7 USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 1
92.74 USD
8 months ago
Mar 07, 2024
Sell 441 K USD
Kliman Gilbert H
Director
- 5000
88.25 USD
8 months ago
Mar 06, 2024
Sell 271 K USD
Kliman Gilbert H
Director
- 3145
86.01 USD
8 months ago
Mar 06, 2024
Sell 442 K USD
Kliman Gilbert H
Director
- 5202
84.93 USD
8 months ago
Feb 29, 2024
Sell 216 K USD
Stapley Marc
Director
- 2437
88.76 USD
8 months ago
Feb 29, 2024
Sell 136 K USD
Stapley Marc
Director
- 1500
90.54 USD
8 months ago
Feb 29, 2024
Sell 211 K USD
Stapley Marc
Director
- 2313
91.21 USD
8 months ago
Feb 27, 2024
Sell 736 K USD
Kliman Gilbert H
Director
- 8000
92 USD
8 months ago
Feb 23, 2024
Sell 1.95 M USD
Gilliam Joseph E
PRESIDENT & COO
- 21414
90.94 USD
8 months ago
Feb 23, 2024
Sell 10.6 M USD
Gilliam Joseph E
PRESIDENT & COO
- 114739
92.33 USD
8 months ago
Feb 23, 2024
Sell 381 K USD
Gilliam Joseph E
PRESIDENT & COO
- 4092
93.05 USD
8 months ago
Feb 23, 2024
Sell 423 K USD
Foley Mark J
Director
- 4560
92.87 USD
9 months ago
Feb 12, 2024
Sell 146 K USD
Gilliam Joseph E
PRESIDENT & COO
- 1512
96.8 USD
9 months ago
Feb 08, 2024
Sell 480 K USD
Gilliam Joseph E
PRESIDENT & COO
- 5000
96.07 USD
9 months ago
Feb 09, 2024
Sell 61 K USD
Gilliam Joseph E
PRESIDENT & COO
- 631
96.7 USD
9 months ago
Feb 07, 2024
Sell 3.14 K USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 33
95 USD
9 months ago
Feb 08, 2024
Sell 35.3 K USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 369
95.65 USD
9 months ago
Feb 08, 2024
Sell 17.4 K USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 181
96.06 USD
9 months ago
Jan 29, 2024
Sell 892 K USD
Gilliam Joseph E
PRESIDENT & COO
- 9476
94.12 USD
9 months ago
Jan 22, 2024
Sell 49.3 K USD
Gilliam Joseph E
PRESIDENT & COO
- 524
94.01 USD
10 months ago
Jan 18, 2024
Sell 43.7 K USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 483
90.42 USD
10 months ago
Jan 18, 2024
Sell 9.11 K USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 100
91.11 USD
10 months ago
Jan 16, 2024
Sell 436 K USD
Gilliam Joseph E
PRESIDENT & COO
- 4890
89.17 USD
10 months ago
Jan 12, 2024
Sell 9.79 K USD
Gilliam Joseph E
PRESIDENT & COO
- 110
89.01 USD
10 months ago
Jan 08, 2024
Sell 187 K USD
Burns Thomas William
CHAIRMAN & CEO
- 2314
80.65 USD
10 months ago
Jan 08, 2024
Sell 1.03 M USD
Burns Thomas William
CHAIRMAN & CEO
- 12614
81.5 USD
10 months ago
Jan 08, 2024
Sell 1.92 M USD
Burns Thomas William
CHAIRMAN & CEO
- 23299
82.38 USD
10 months ago
Jan 08, 2024
Sell 1.49 M USD
Burns Thomas William
CHAIRMAN & CEO
- 17873
83.38 USD
10 months ago
Jan 09, 2024
Sell 425 USD
Burns Thomas William
CHAIRMAN & CEO
- 5
85 USD
10 months ago
Jan 09, 2024
Sell 6.33 K USD
Burns Thomas William
CHAIRMAN & CEO
- 73
86.74 USD
10 months ago
Jan 08, 2024
Sell 328 K USD
Burns Thomas William
CHAIRMAN & CEO
- 3900
84.21 USD
10 months ago
Jan 09, 2024
Sell 3.23 K USD
Burns Thomas William
CHAIRMAN & CEO
- 37
87.33 USD
10 months ago
Jan 02, 2024
Sell 3.97 M USD
Burns Thomas William
CHAIRMAN & CEO
- 51764
76.69 USD
10 months ago
Jan 02, 2024
Sell 2.72 M USD
Burns Thomas William
CHAIRMAN & CEO
- 35086
77.66 USD
10 months ago
Jan 02, 2024
Sell 640 K USD
Burns Thomas William
CHAIRMAN & CEO
- 8150
78.49 USD
10 months ago
Dec 21, 2023
Sell 405 K USD
Gilliam Joseph E
PRESIDENT & COO
- 4835
83.7 USD
10 months ago
Dec 21, 2023
Sell 1.44 M USD
Gilliam Joseph E
PRESIDENT & COO
- 16965
84.97 USD
10 months ago
Dec 21, 2023
Sell 274 K USD
Gilliam Joseph E
PRESIDENT & COO
- 3200
85.58 USD
10 months ago
Dec 21, 2023
Sell 49.6 K USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 583
85.14 USD
10 months ago
Dec 22, 2023
Sell 85.3 USD
Burns Thomas William
CHAIRMAN & CEO
- 1
85.32 USD
10 months ago
Dec 21, 2023
Sell 6.79 M USD
Burns Thomas William
CHAIRMAN & CEO
- 79684
85.21 USD
11 months ago
Dec 15, 2023
Sell 101 K USD
Thurman Alex R.
SVP & CHIEF FINANCIAL OFFICER
- 1270
79.8 USD
11 months ago
Dec 14, 2023
Sell 696 K USD
Stapley Marc
Director
- 9206
75.61 USD
11 months ago
Dec 14, 2023
Sell 538 K USD
Stapley Marc
Director
- 7044
76.35 USD
11 months ago
Dec 15, 2023
Sell 2.1 M USD
Burns Thomas William
CHAIRMAN & CEO
- 26195
80.3 USD
11 months ago
Dec 14, 2023
Sell 1.34 M USD
Burns Thomas William
CHAIRMAN & CEO
- 17688
75.6 USD
11 months ago
Dec 15, 2023
Sell 2.35 M USD
Burns Thomas William
CHAIRMAN & CEO
- 28835
81.38 USD
11 months ago
Dec 15, 2023
Sell 406 K USD
Burns Thomas William
CHAIRMAN & CEO
- 4970
81.77 USD
11 months ago
Dec 14, 2023
Sell 940 K USD
Burns Thomas William
CHAIRMAN & CEO
- 12312
76.36 USD
1 year ago
Oct 02, 2023
Sell 1.04 M USD
Burns Thomas William
CHAIRMAN & CEO
- 14726
70.75 USD
1 year ago
Oct 02, 2023
Sell 723 K USD
Burns Thomas William
CHAIRMAN & CEO
- 10100
71.54 USD
1 year ago
Oct 02, 2023
Sell 870 K USD
Burns Thomas William
CHAIRMAN & CEO
- 11963
72.7 USD
1 year ago
Oct 02, 2023
Sell 580 K USD
Burns Thomas William
CHAIRMAN & CEO
- 7879
73.67 USD
1 year ago
Oct 02, 2023
Sell 24.7 K USD
Burns Thomas William
CHAIRMAN & CEO
- 332
74.36 USD
1 year ago
Aug 04, 2023
Sell 746 K USD
Kliman Gilbert H
Director
- 10000
74.56 USD
1 year ago
Jul 19, 2023
Sell 16 K USD
Burns Thomas William
CHAIRMAN & CEO
- 200
80.01 USD
1 year ago
Jul 14, 2023
Sell 3.3 M USD
Gilliam Joseph E
PRESIDENT & COO
- 42099
78.34 USD
1 year ago
Jul 14, 2023
Sell 255 K USD
Burns Thomas William
CHAIRMAN & CEO
- 3342
76.32 USD
1 year ago
Jul 14, 2023
Sell 884 K USD
Burns Thomas William
CHAIRMAN & CEO
- 11470
77.05 USD
1 year ago
Jul 14, 2023
Sell 288 K USD
Burns Thomas William
CHAIRMAN & CEO
- 3689
78.18 USD
1 year ago
Jul 14, 2023
Sell 776 K USD
Burns Thomas William
CHAIRMAN & CEO
- 9799
79.16 USD
1 year ago
Jul 14, 2023
Sell 136 K USD
Burns Thomas William
CHAIRMAN & CEO
- 1700
79.71 USD
1 year ago
Jul 12, 2023
Sell 197 K USD
Gilliam Joseph E
PRESIDENT & COO
- 2700
73.09 USD
1 year ago
Jul 10, 2023
Sell 929 K USD
Burns Thomas William
CHAIRMAN & CEO
- 13111
70.86 USD
1 year ago
Jul 10, 2023
Sell 23.4 K USD
Burns Thomas William
CHAIRMAN & CEO
- 329
71.23 USD
1 year ago
Jul 07, 2023
Sell 9.31 K USD
Burns Thomas William
CHAIRMAN & CEO
- 133
70 USD
1 year ago
Jul 03, 2023
Sell 1.57 M USD
Burns Thomas William
CHAIRMAN & CEO
- 22570
69.38 USD
1 year ago
Jul 03, 2023
Sell 269 K USD
Burns Thomas William
CHAIRMAN & CEO
- 3830
70.27 USD
1 year ago
Jul 05, 2023
Sell 352 K USD
Burns Thomas William
CHAIRMAN & CEO
- 5027
70.02 USD
1 year ago
Jun 28, 2023
Sell 1.88 M USD
Burns Thomas William
CHAIRMAN & CEO
- 26810
70.19 USD
1 year ago
Jun 08, 2023
Sell 223 K USD
Burns Thomas William
CHAIRMAN & CEO
- 3190
70.02 USD
1 year ago
Jun 07, 2023
Sell 333 K USD
Burns Thomas William
CHAIRMAN & CEO
- 5001
66.54 USD
1 year ago
Jun 07, 2023
Sell 653 K USD
Burns Thomas William
CHAIRMAN & CEO
- 9701
67.32 USD
1 year ago
Jun 06, 2023
Sell 495 K USD
Burns Thomas William
CHAIRMAN & CEO
- 7618
65.04 USD
1 year ago
Jun 07, 2023
Sell 182 K USD
Burns Thomas William
CHAIRMAN & CEO
- 2680
67.99 USD
1 year ago
Jun 02, 2023
Sell 8.52 K USD
Burns Thomas William
CHAIRMAN & CEO
- 142
60 USD
1 year ago
May 19, 2023
Sell 60.2 USD
Burns Thomas William
CHAIRMAN & CEO
- 1
60.21 USD
1 year ago
May 23, 2023
Sell 420 USD
Burns Thomas William
CHAIRMAN & CEO
- 7
60 USD
1 year ago
May 17, 2023
Sell 37.2 K USD
Burns Thomas William
CHAIRMAN & CEO
- 620
60.038 USD
1 year ago
May 18, 2023
Sell 702 K USD
Burns Thomas William
CHAIRMAN & CEO
- 11662
60.174 USD
1 year ago
May 15, 2023
Sell 232 K USD
Burns Thomas William
CHAIRMAN & CEO
- 3864
60.026 USD
1 year ago
May 16, 2023
Sell 222 K USD
Burns Thomas William
CHAIRMAN & CEO
- 3704
60.009 USD
2 years ago
Aug 04, 2022
Sell 178 K USD
Kliman Gilbert H
director:
- 3362
53.0129 USD
3 years ago
May 06, 2021
Sell 300 K USD
Gilliam Joseph E
CFO, SVP Corporate Development
- 3657
81.95 USD
3 years ago
May 06, 2021
Sell 94.5 K USD
Gilliam Joseph E
CFO, SVP Corporate Development
- 1143
82.71 USD
3 years ago
May 06, 2021
Sell 8.36 K USD
Gilliam Joseph E
CFO, SVP Corporate Development
- 100
83.61 USD
3 years ago
May 06, 2021
Sell 8.5 K USD
Gilliam Joseph E
CFO, SVP Corporate Development
- 100
85 USD
3 years ago
May 03, 2021
Sell 1.3 M USD
Gilliam Joseph E
CFO, SVP Corporate Development
- 13992
93.18 USD
3 years ago
May 03, 2021
Sell 496 K USD
Gilliam Joseph E
CFO, SVP Corporate Development
- 5258
94.26 USD
3 years ago
May 03, 2021
Sell 71.3 K USD
Gilliam Joseph E
CFO, SVP Corporate Development
- 750
95.02 USD
3 years ago
Mar 15, 2021
Sell 439 K USD
Gilliam Joseph E
CFO, SVP Corporate Development
- 5000
87.88 USD
3 years ago
Feb 09, 2021
Sell 1.11 M USD
Gilliam Joseph E
CFO, SVP Corporate Development
- 11488
96.49 USD
3 years ago
Feb 09, 2021
Sell 219 K USD
Gilliam Joseph E
CFO, SVP Corporate Development
- 2262
97.02 USD
3 years ago
Feb 01, 2021
Sell 1.14 M USD
Calcaterra Chris M.
Chief Operating Officer
- 13201
86.6477 USD
3 years ago
Feb 01, 2021
Sell 529 K USD
Calcaterra Chris M.
Chief Operating Officer
- 6030
87.7853 USD
3 years ago
Feb 01, 2021
Sell 2.17 M USD
Calcaterra Chris M.
Chief Operating Officer
- 24401
88.7377 USD
3 years ago
Feb 01, 2021
Sell 1.5 M USD
Calcaterra Chris M.
Chief Operating Officer
- 16785
89.4434 USD
3 years ago
Dec 01, 2020
Sell 3.36 M USD
LINK WILLIAM J PHD
Director
- 49400
67.9573 USD
3 years ago
Dec 01, 2020
Sell 41.2 K USD
LINK WILLIAM J PHD
Director
- 600
68.7197 USD
4 years ago
May 26, 2020
Sell 7.6 M USD
Burns Thomas William
Chief Executive Officer
- 193989
39.1926 USD
4 years ago
May 26, 2020
Sell 535 K USD
Burns Thomas William
Chief Executive Officer
- 13458
39.7231 USD
4 years ago
May 20, 2020
Sell 15.2 K USD
Burns Thomas William
Chief Executive Officer
- 400
38.0533 USD
7. News
Glaukos Announces Participation in Upcoming Investor Conferences ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel Healthcare Conference on Tuesday, November 19, 2024, at 12:40 p.m. ET in New York City, NY Stephens Annual Investment Conference on Wednesday, Novembe. businesswire.com - 1 week ago
Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 1 week ago
Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds Glaukos Corp GKOS reported on Monday third-quarter sales of $96.7 million, up 24% year-over-year, beating the consensus of $91.49 million. benzinga.com - 1 week ago
GKOS Stock Declines Despite Q3 Earnings & Revenues Beat Estimates Glaukos' third-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx remain a cause of concern. zacks.com - 1 week ago
Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript Call Start: 16:30 January 1, 0000 5:31 PM ET Glaukos Corporation. (NYSE:GKOS ) Q3 2024 Earnings Conference Call November 04, 2024, 04:30 PM ET Company Participants Chris Lewis - VP, IR and Corporate Affairs Tom Burns - Chairman and CEO Joe Gilliam - President and COO Alex Thurman - CFO Conference Call Participants Tom Stephan - Stifel Lawrence Biegelsen - Wells Fargo Ryan Zimmerman - BTIG Matthew O'Brien - Piper Sandler Allen Gong - JPMorgan David Saxon - Needham Michael Sarcone - Jefferies Joanne Wuensch - Citigroup Steve Lichtman - Oppenheimer Anthony Petrone - Mizuho Operator Welcome to Glaukos Corporation's Third Quarter 2024 Financial Results Conference Call. seekingalpha.com - 1 week ago
Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates Glaukos (GKOS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.50 per share a year ago. zacks.com - 1 week ago
Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 weeks ago
GKOS Stock Rises on Positive Phase 3 Confirmatory Trial for Epioxa Glaukos announces positive second Phase 3 confirmatory pivotal trial for Epioxa. zacks.com - 1 month ago
Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held October 18-21, 2024, in Chicago, IL. Glaukos will be exhibiting onsite at booth #2608. In addition, Glauko. businesswire.com - 1 month ago
Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4 ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2024 financial results after the market close on Monday, November 4, 2024. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on November 4, 2024. A link to t. businesswire.com - 1 month ago
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now GKOS continues to benefit from a robust demand for its products and expansion in new markets. A strong development pipeline raises optimism. zacks.com - 1 month ago
Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally? GKOS stock is being driven by strong product demand, international expansion and pipeline progress, which position it for long-term growth despite supply risks. zacks.com - 1 month ago
8. Profile Summary

Glaukos Corporation GKOS

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 7.63 B
Dividend Yield 0.00%
Description Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Contact 229 Avenida Fabricante, San Clemente, CA, 92672 https://www.glaukos.com
IPO Date June 25, 2015
Employees 907
Officers Ms. Diana A. Scherer Vice President of Compliance & Deputy General Counsel Dr. Tomas Navratil Ph.D. Chief Development Officer Dr. Mory Gharib Ph.D. Co-Founder Mr. L. Jay Katz FACS, M.D. Chief Medical Officer Ms. Michele M. Allegretto Senior Vice President of Human Resources Mr. Chris M. Calcaterra Executive Vice President of Global Commercial Operations Mr. Joseph E. Gilliam President & Chief Operating Officer Mr. Christopher William Lewis Vice President of Investor Relations & Corporate Affairs Mr. Thomas William Burns Chairman & Chief Executive Officer Mr. Alex R. Thurman Senior Vice President & Chief Financial Officer